192 related articles for article (PubMed ID: 32950461)
1. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
[TBL] [Abstract][Full Text] [Related]
2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
3. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
[TBL] [Abstract][Full Text] [Related]
4. Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
Fernandez-Alvarez R; Gonzalez-Rodriguez AP; Gonzalez ME; Rubio-Castro A; Dominguez-Iglesias F; Solano J; Alonso-Nogues E; Fernandez-Alvarez C; Zanabili Y; Alonso JM; Payer AR; Vicente JM; Medina J; Sancho JM
Leuk Lymphoma; 2015; 56(11):3096-102. PubMed ID: 25860241
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study.
Makiyama J; Imaizumi Y; Watanabe H; Fujioka M; Chiwata M; Kitanosono H; Nakashima J; Miyazaki Y; Yoshida S
Intern Med; 2021 Mar; 60(5):709-718. PubMed ID: 33087662
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
[TBL] [Abstract][Full Text] [Related]
8. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
[TBL] [Abstract][Full Text] [Related]
9. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
10. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
[TBL] [Abstract][Full Text] [Related]
11. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
[TBL] [Abstract][Full Text] [Related]
13. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
[TBL] [Abstract][Full Text] [Related]
14. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
16. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
17. Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.
Zawati I; Adouni O; Finetti P; Manai M; Manai M; Gamoudi A; Birnbaum D; Bertucci F; Mezlini A
Cancer Radiother; 2020 Jun; 24(3):206-214. PubMed ID: 32171674
[TBL] [Abstract][Full Text] [Related]
18. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
[TBL] [Abstract][Full Text] [Related]
19. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
[TBL] [Abstract][Full Text] [Related]
20. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]